Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Knopp Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Austria, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, France, Georgia, Germany, Hungary, Italy, Korea, Lithuania, Macedonia, Mexico, Poland, Puerto Rico, Romania, Serbia, South Africa, South Korea, Spain, Taiwan, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Asthma|Pulmonary Eosinophilia
Phase 2: Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
EXHALE-5 | P3 |
Enrolling by invitation |
Pulmonary Eosinophilia|Asthma |
2027-06-01 |
|
AR-DEX-22-04 | P3 |
Unknown Status |
Asthma |
2027-02-20 |
|
jRCT2031240072 | P3 |
Not yet recruiting |
Asthma |
2026-12-11 |
|
AR-DEX-22-01 | P3 |
Unknown Status |
Asthma |
2026-07-27 |